Inrebic
Payments companies reported to CMS as associated with Inrebic. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Inrebic, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Inrebic
These are the largest totals companies reported as associated with Inrebic. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Bart Scott | Seattle, WA | Medical Oncology | $8,563.85 |
| Srdan Verstovsek | Houston, TX | Medical Oncology | $4,498.00 |
| Moshe Talpaz | Ann Arbor, MI | Medical Oncology | $3,854.50 |
| John Mascarenhas | New York, NY | Hematology & Oncology | $2,580.00 |
| Bipinkumar Amin | Watertown, SD | Hematology & Oncology | $185.44 |
| Vijay Rao | Watertown, SD | Hematology & Oncology | $132.86 |
| Prithviraj Bose | Houston, TX | Hematology & Oncology | $47.26 |
| Julie Huynh-Lu | Houston, TX | Physician Assistant | $25.00 |
Prescribed Inrebic?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.